{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:14:15Z","timestamp":1773332055029,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.acvd.2025.08.008","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T18:37:22Z","timestamp":1758134242000},"page":"192-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-6551","authenticated-orcid":false,"given":"Francois","family":"Schiele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Borsik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2025.08.008_bib0190","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.08.008_bib0195","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2025.08.008_bib0200","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.08.008_bib0205","doi-asserted-by":"crossref","first-page":"100649","DOI":"10.1016\/j.ajpc.2024.100649","article-title":"The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: lower for longer is better","volume":"18","author":"Mhaimeed","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.acvd.2025.08.008_bib0210","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","article-title":"Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor","volume":"15","author":"Nawrocki","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2025.08.008_bib0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2021.03.007","article-title":"Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: five years of clinical follow-up from 164,565 post-myocardial infarction patients","volume":"332","author":"Schiele","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2025.08.008_bib0220","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","article-title":"Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement","volume":"225","author":"Banach","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2025.08.008_bib0225","doi-asserted-by":"crossref","first-page":"e185554","DOI":"10.1001\/jamanetworkopen.2018.5554","article-title":"Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and\/or ezetimibe","volume":"1","author":"Khunti","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.acvd.2025.08.008_bib0230","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.08.008_bib0235","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.08.008_bib0240","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.acvd.2025.08.008_bib0245","doi-asserted-by":"crossref","first-page":"107141","DOI":"10.1016\/j.vph.2023.107141","article-title":"The effect of the 2019 ESC\/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: the ACS EuroPath IV project","volume":"148","author":"Laufs","year":"2023","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.acvd.2025.08.008_bib0250","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.acvd.2025.08.008_bib0255","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.08.008_bib0260","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amjcard.2007.09.096","article-title":"Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10\u00a0mg) for statin intolerant high-risk patients","volume":"101","author":"Athyros","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2025.08.008_bib0265","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolaemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.acvd.2025.08.008_bib0270","doi-asserted-by":"crossref","first-page":"e000134","DOI":"10.1136\/bmjmed-2022-000134","article-title":"Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies","volume":"1","author":"Wang","year":"2022","journal-title":"BMJ Med"},{"key":"10.1016\/j.acvd.2025.08.008_bib0275","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11886-004-0052-5","article-title":"Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways","volume":"6","author":"Patel","year":"2004","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.acvd.2025.08.008_bib0280","first-page":"84","article-title":"Bempedoic acid: a novel oral LDL-cholesterol lowering agent","volume":"14","author":"Jialal","year":"2022","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"10.1016\/j.acvd.2025.08.008_bib0285","doi-asserted-by":"crossref","first-page":"e012352","DOI":"10.1161\/JAHA.119.012352","article-title":"CLEAR serenity trial: more clarity for the future of bempedoic acid in patients unable to take statins?","volume":"8","author":"Jia","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2025.08.008_bib0290","unstructured":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9. Direction de la recherche, des \u00e9tudes, de l\u2019\u00e9valuation et des statistiques (DREES). D\u00e9mographie des professionnels de sant\u00e9, https:\/\/drees.shinyapps.io\/demographie-ps\/ [accessed 25 July 2024]."},{"key":"10.1016\/j.acvd.2025.08.008_bib0295","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3390\/jcm12020705","article-title":"Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany (2017 to 2020)","volume":"12","author":"Parhofer","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.acvd.2025.08.008_bib0300","series-title":"Lipid-lowering therapy use and LDL-C goal attainment in France: results from 1-year follow-up of the European observational SANTORINI study","author":"Ferri\u00e8res","year":"2024"},{"key":"10.1016\/j.acvd.2025.08.008_bib0305","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41598-023-50847-1","article-title":"LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation study","volume":"14","author":"Katzmann","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.acvd.2025.08.008_bib0310","first-page":"329","article-title":"Lipid-lowering treatment and the lipid goals attainment in patients with a very high cardiovascular risk","volume":"10","author":"Lis","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.acvd.2025.08.008_bib0315","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1093\/eurheartj\/ehad655.2810","article-title":"Effectiveness and safety of bempedoic acid in routine clinical practice: 1-year follow-up snapshot of the MILOS German cohort","volume":"44","author":"Gouni-Berthold","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.08.008_bib0320","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1093\/eurheartj\/ehz458","article-title":"Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France","volume":"40","author":"Giral","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.08.008_bib0325","doi-asserted-by":"crossref","first-page":"e2136802","DOI":"10.1001\/jamanetworkopen.2021.36802","article-title":"Statin discontinuation and cardiovascular events among older people in Denmark","volume":"4","author":"Thompson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.acvd.2025.08.008_bib0330","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2015.03.002","article-title":"IMPROVE-IT clinical implications. Should the \u201chigh-intensity cholesterol-lowering therapy\u201d strategy replace the \u201chigh-intensity statin therapy\u201d?","volume":"240","author":"Masana","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2025.08.008_bib0335","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11886-020-01326-w","article-title":"Reasons why combination therapy should be the new standard of care to achieve the LDL-cholesterol targets: lipid-lowering combination therapy","volume":"22","author":"Masana","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.acvd.2025.08.008_bib0340","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2025.08.008_bib0345","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pcad.2023.03.001","article-title":"Bempedoic acid in the management of lipid disorders and cardiovascular risk: 2023 position paper of the International Lipid Expert Panel (ILEP)","volume":"79","author":"Banach","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2025.08.008_bib0350","doi-asserted-by":"crossref","first-page":"277","DOI":"10.12997\/jla.2023.12.3.277","article-title":"Lipid-lowering efficacy of combination therapy with moderate-intensity statin and ezetimibe versus high-intensity statin monotherapy: a randomized, open-label, non-inferiority trial from Korea","volume":"12","author":"Choi","year":"2023","journal-title":"J Lipid Atheroscler"},{"key":"10.1016\/j.acvd.2025.08.008_bib0355","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.08.008_bib0360","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.08.008_bib0365","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.08.008_bib0370","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC Guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213625004632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213625004632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:07:13Z","timestamp":1773176833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213625004632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1875213625004632"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2025.08.008","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2025.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}